文献速递白血病

解读TP53突变急性髓系白血病的分子驱动因素:临床意义与预后洞察

Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.
PubMed 文献 · Br J Haematol · 2025-11-30

该研究回顾性分析193例TP53突变AML患者,发现VEN+HMA方案较3+7方案获得更高CRc(53.8% vs 30.2%,p=0.018)。TP53 V272突变与较低复发率相关,单打击组OS优于多打击组,CEBPA bZIP框内突变和RUNX1-RUNX1T1融合基因患者OS延长。多因素分析确定RUNX1-RUNX1T1融合、RUNX1突变和FLT3-ITD突变是独立预后因素。

要点

  • TP53突变AML中VEN+HMA方案CRc优于3+7方案
  • TP53单打击组OS优于多打击组
  • RUNX1-RUNX1T1融合基因提示较好预后

核心结论

  • 分子因素影响TP53突变AML患者的预后,其中TP53突变位点尤其值得关注。

研究设计与样本

  • 回顾性分析193例TP53突变急性髓系白血病患者。

主要发现

  • VEN+HMA方案组CRc为53.8%,3+7方案组为30.2%(p=0.018)。
  • TP53 V272突变组复发率为0%,对照组为35.2%(p=0.041)。
  • 单打击组中位OS为14.3个月,多打击组为10.8个月(p=0.029)。
  • CEBPA bZIP框内突变组中位OS为25.2个月,对照组为13.8个月(p=0.036)。
  • RUNX1-RUNX1T1融合基因阳性组中位OS为31.1个月,阴性组为13.7个月(p=0.002)。

关键数值与推荐

  • 多因素分析显示RUNX1-RUNX1T1融合基因HR=0.23(95%CI 0.08-0.63,p=0.005)。
  • 多因素分析显示RUNX1突变HR=1.84(95%CI 1.14-2.96,p=0.012)。
  • 多因素分析显示FLT3-ITD突变HR=3.14(95%CI 1.80-5.47,p=0.001)。

临床怎么用

  • 对TP53突变AML患者可优先考虑VEN+HMA方案。
  • 评估TP53突变位点、打击数目及共存突变以细化预后分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to investigate the distinct clinical characteristics and molecular features of TP53-mutant acute myeloid leukaemia (AML) patients. We retrospectively analysed 193 TP53-mutant AML patients. Better responses were observed in patients treated with the venetoclax in combination with hypomethylating agent (VEN + HMA) regimen compared to those receiving the '3 + 7' regimens (composite complete remission [CRc], 53.8% vs. 30.2%; p = 0.018). TP53 V272 mutation was associated with a lower relapse rate (0% vs. 35.2%; p = 0.041). The single hit group exhibited superior OS compared to the multi-hit group (the median overall survival [OS]: 14.3 months vs. 10.8 months; p = 0.029). TP53-mutant AML patients with CEBPA bZIP in-frame mutations showed prolonged OS (the median OS: 25.2 months vs. 13.8 months; p = 0.036). Better prognoses were also shown in patients with RUNX1-RUNX1T1 fusion gene (the median OS: 31.1 months vs. 13.7 months; p = 0.002). Multivariate analysis identified three significant prognostic factors for OS: RUNX1-RUNX1T1 fusion gene (hazard ratio [HR] = 0.23, 95% confidence interval [CI], 0.08-0.63; p = 0.005), RUNX1 mutation (HR = 1.84; 95% CI, 1.14-2.96; p = 0.012) and FLT3-ITD mutation (HR = 3.14; 95% CI, 1.80-5.47; p = 0.001). In conclusion, molecular factors matter in influencing the prognosis of TP53-mutant AML patients. Among them, TP53 mutation sites merit particular attention.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wang LY, Gao HT, Fu Q, et al. Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights. Br J Haematol. 2025. PMID: 41320982. doi:10.1111/bjh.70271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。